In Vivo Model Development for Retinal Degeneration

Ace Therapeutics offers a comprehensive in vivo animal model development service for retinal degeneration research, supporting drug discovery and preclinical validation. Our portfolio features a wide array of scientifically validated mouse and rat models that accurately recapitulate the pathophysiology of human retinal degenerative diseases. We provide tailored solutions to meet the unique research needs of our partners in academia, biotechnology, and pharmaceutical industries.

Retinal degeneration encompasses a group of progressive, sight-threatening disorders such as retinitis pigmentosa, age-related macular degeneration, and inherited retinal dystrophies. Animal models are essential tools for elucidating disease mechanisms and evaluating novel therapies. At Ace Therapeutics, we utilize a diverse range of species and strains, including Mus musculus (e.g., C57BL/6J, Balb/c, 129SvJ, Rd1, Rd10, FVB/N) and Rattus norvegicus (e.g., Long Evans, Sprague Dawley, Wistar), each selected for their genetic backgrounds, susceptibility to retinal injury, and translational relevance. Our models span chemically-induced, light-induced, and genetic paradigms, enabling robust and reproducible assessment of therapeutic efficacy and safety.

Chemically-Induced Models

Chemically-induced retinal degeneration models use agents such as sodium iodate (NaIO3), cisplatin, NMDA, or 1-methyl-2-oxohydrazinecarboxamide to selectively damage retinal cells. These agents are administered systemically or intraocularly to induce rapid and reproducible degeneration of the retinal pigment epithelium or photoreceptors. Advantages include precise control over injury timing and severity, high reproducibility, and suitability for evaluating acute neuroprotective interventions. These models are widely used for screening drug candidates, studying retinal toxicology, and investigating mechanisms of cell death.

Light-Induced Models

Light-induced models expose animals to controlled illumination (white, blue, or fluorescent light) to trigger photoreceptor degeneration through oxidative stress and apoptosis. Mice or rats of specific strains (e.g., Balb/cJ, C3H, Long Evans) are subjected to defined light intensities and durations, mimicking environmental or pathological light exposure. Key advantages include non-invasive induction, ability to model spatially restricted lesions, and clinical relevance to light-associated retinal disorders. These models are ideal for assessing neuroprotective therapies, antioxidant strategies, and retinal repair mechanisms.

Genetic and Transgenic Models

Genetic models encompass naturally occurring mutants (e.g., Rd1, Rd10, FVB/N with Pde6b mutations), knockouts (e.g., Cdhr1, Mertk, Reep6, Rp2, Rpgr, Ttll5), and transgenic lines (e.g., Nrl, RHO). These models recapitulate the genetic heterogeneity and progressive nature of human inherited retinal diseases. Generation involves targeted gene editing or breeding of established mutant lines. Advantages include faithful modeling of disease genetics, chronic progression, and suitability for long-term intervention studies. Genetic models are indispensable for gene therapy, cell replacement, and mechanistic studies of retinal degeneration.

Ace Therapeutics delivers end-to-end in vivo retinal degeneration model services, encompassing model selection or custom development, induction and validation, therapeutic administration, and comprehensive phenotypic analysis. Key efficacy endpoints include retinal morphology (histology, OCT), functional assessment (ERG, optokinetic tracking), molecular profiling (qPCR, immunohistochemistry), and quantification of cell survival or death. Our analytical capabilities extend to advanced imaging, biomarker analysis, and pharmacokinetics. Rigorous quality control is maintained through standardized protocols, validated reagents, and experienced technical staff to ensure data reliability and reproducibility.

Partnering with Ace Therapeutics grants you access to a broad suite of validated retinal degeneration models, expert scientific support, and state-of-the-art analytical platforms. Our commitment to quality and customization accelerates your preclinical research, enabling efficient translation of therapeutic discoveries to the clinic. Contact us today to discuss your project needs and discover how we can help advance your retinal degeneration research.